MK0626

Known as: MK-0626 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
0520122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
AIMS Exercise capacity is reduced in heart failure (HF) patients, due mostly to skeletal muscle abnormalities including impaired… (More)
Is this relevant?
2016
2016
Although the two anti-diabetic drugs, dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 (GLP-1) receptor… (More)
Is this relevant?
2015
2015
OBJECTIVE Intestinal overproduction of atherogenic chylomicron particles postprandially is an important component of diabetic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2014
2014
Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic… (More)
Is this relevant?
2014
2014
OBJECTIVE Consumption of a high-fat/high-fructose Western diet (WD) is linked to rising obesity and heart disease, particularly… (More)
Is this relevant?
2014
2014
AIM To investigate the mechanism and in vivo effects of MK-0626, a dipeptidyl peptidase-4 inhibitor, on hepatic steatosis using… (More)
Is this relevant?
2014
2014
Glucagon-like peptide-2 (GLP-2) has been shown to be effective in patients with short bowel syndrome (SBS), but it is rapidly… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2014
2014
Therapies to prevent renal injury in obese hypertensive individuals are being actively sought due to the obesity epidemic arising… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
Dipeptidyl peptidase-4 (DPP-4) inhibitor and exercise have proven to be effective treatments for diabetes. However, the effects… (More)
Is this relevant?
2012
2012
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted into the circulation by the intestinal L cell. The… (More)
Is this relevant?